核医学nuclearmedicine.ppt

111In-DOTA-Tyr3-Octreotate Scintigraphy Nodes 1 h post-injection 4 h post-injection 24 h post-injection PNA Imaging of Normal Dog Partial Remission Initial Scan Remission Scan Complete Remission Initial Scan Remission Scan Relapse Scan Hypothesis 3 Combined radionuclide and antisense therapy may act synergistically or additively with respect to cell proliferation and viability in an in vitro model of B-cell lymphoma. Western Blot Analysis Tubulin bcl-2 1 2 3 4 5 1. Cells without treatment 2. Cells treated with 2 μg of DOTA-anti-bcl-2-PNA-Tyr3-octreotate for 48 h 3. Cells without treatment 4. Cells treated with 2 μg of DOTA-nonsense-PNA-Tyr3-octreotate for 48h 5. Cells treated with 2 μg of DOTA-anti-bcl-2-PNA-Ala for 48 h Cell Viability Assay Day 2 p0.002 Day 3 p0.005 TUNEL Assays Anti-bcl-2 + Anti-FLIP Anti-bcl-2 + CH11 Anti-bcl-2 Anti-FLIP + CH11 Anti-bcl-2 + Anti-FLIP Anti-bcl-2 + CH11 Anti-bcl-2 Anti-FLIP + CH11 SH-SY5Y IMR-32 Acknowledgments Dr. Carolyn Anderson Washington University Dr. Henry VanBrocklin Lawrence Berkeley Lab Dr. Joanna Fowler Brookhaven National Lab Dr. Gregory Daniel University of Tennessee Dr. Alan Ketring University of Missouri Dr. Wynn Volkert University of Missouri * * * -Veterinary nuclear medicine imaging facilities at MU allowed us to diagnose and monitor the bone cancer in patient dogs * -First documented cures of dogs with bone cancer, without amputation, reported in the literature. * The development Quadramet exemplifies the translational research capabilities at MU: from the and production of the radioisotope (Sm-153) and the identification of the phosphonate comppound, (EDTMP) which targets bone cancer to the initial clinical trials in human patients. * Consistent with the biodistribution study that kidneys were the primary organ of accumulation of the PNA conjugates. * This is an scintigraphy scan of a normal healthy patient. There appears to be no specific i